Abstract
Therapies that are believed to target the underlying mechanisms of Alzheimers disease have now reached human clinical trials, with the number of agents in late stage development having increased dramatically in recent years. Primary targets include beta-amyloid, whose presence and accumulation in the brain is thought to contribute to the development of Alzheimers disease, and tau protein which, when hyperphosphorylated, results in the formation of neurofibrillary tangles of paired helical filaments, also believed to be involved in the pathogenesis of Alzheimers disease. In the review, the current status of Alzheimers Disease therapies under study is discussed, including the scientific basis for each strategy.
Keywords: Alzheimer's disease, clincal trials, drug development for Alzheimer's disease, mild cognitive impairment
Reviews on Recent Clinical Trials
Title: The Pulse of Drug Development for Alzheimers Disease
Volume: 5 Issue: 1
Author(s): Michael S. Rafii
Affiliation:
Keywords: Alzheimer's disease, clincal trials, drug development for Alzheimer's disease, mild cognitive impairment
Abstract: Therapies that are believed to target the underlying mechanisms of Alzheimers disease have now reached human clinical trials, with the number of agents in late stage development having increased dramatically in recent years. Primary targets include beta-amyloid, whose presence and accumulation in the brain is thought to contribute to the development of Alzheimers disease, and tau protein which, when hyperphosphorylated, results in the formation of neurofibrillary tangles of paired helical filaments, also believed to be involved in the pathogenesis of Alzheimers disease. In the review, the current status of Alzheimers Disease therapies under study is discussed, including the scientific basis for each strategy.
Export Options
About this article
Cite this article as:
Rafii S. Michael, The Pulse of Drug Development for Alzheimers Disease, Reviews on Recent Clinical Trials 2010; 5 (1) . https://dx.doi.org/10.2174/157488710790820490
DOI https://dx.doi.org/10.2174/157488710790820490 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bioinformatics Comparison of G Protein of Isfahan Virus with the Same Proteins of Two Other Closely Related Viruses of the Genus Vesiculovirus
Protein & Peptide Letters Inflammatory Risk Factors and Pathologies Associated with Alzheimers Disease
Current Alzheimer Research A Role for Leptin in the Systemic Inflammatory Response Syndrome (SIRS) and in Immune Response, an Update
Current Medicinal Chemistry Peptides as Signaling Inhibitors for Mammalian MAP Kinase Cascades
Current Pharmaceutical Design TRIM65 in White Matter Lesions, Innate Immunity, and Tumor
Current Molecular Pharmacology Host Innate Immune Responses to Microbial Pathogens
Current Vascular Pharmacology The Role of VE-cadherin in Blood-brain Barrier Integrity Under Central Nervous System Pathological Conditions
Current Neuropharmacology Brain Targeted Drug Delivery: Factors, Approaches and Patents
Recent Patents on Nanomedicine Viral Protein Functions Study by Affinity Modification
Mini-Reviews in Medicinal Chemistry Neurological Manifestations of COVID-19 and the Importance of Magnetic Resonance Imaging
CNS & Neurological Disorders - Drug Targets Inhibition of Viral-Induced Membrane Fusion by Peptides
Protein & Peptide Letters ABC Transporters in Neurological Disorders: An Important Gateway for Botanical Compounds Mediated Neuro-Therapeutics
Current Topics in Medicinal Chemistry Ribonucleases and ImmunoRNases as Anticancer Drugs
Current Pharmaceutical Design EDITORIAL
Current Signal Transduction Therapy The Role of CXCR3 in Neurological Diseases
Current Neuropharmacology Catatonia: A Brief Update
Current Psychiatry Reviews Opiate Drug Use and the Pathophysiology of NeuroAIDS
Current HIV Research A Case Presentation of Atypical X-linked Adrenoleukodystrophy: Initial Experience with ASL Technique
Current Medical Imaging Immunotherapy, Vascular Pathology, and Microhemorrhages in Transgenic Mice
CNS & Neurological Disorders - Drug Targets Plasmid DNA Manufacturing Technology
Recent Patents on Biotechnology